- Home
- KIND vs MDXG Comparison
KIND vs MDXG Comparison
Compare KIND & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- MDXG
- Stock Information
- Founded
- KIND 2011
- MDXG 2006
- Country
- KIND United States
- MDXG United States
- Employees
- KIND N/A
- MDXG N/A
- Industry
- KIND Computer Software: Programming Data Processing
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- MDXG Health Care
- Exchange
- KIND Nasdaq
- MDXG Nasdaq
- Market Cap
- KIND 993.6M
- MDXG 1.1B
- IPO Year
- KIND N/A
- MDXG N/A
- Fundamental
- Price
- KIND $2.37
- MDXG $7.46
- Analyst Decision
- KIND Hold
- MDXG Strong Buy
- Analyst Count
- KIND 2
- MDXG 5
- Target Price
- KIND $2.75
- MDXG $12.00
- AVG Volume (30 Days)
- KIND 2.0M
- MDXG 1.0M
- Earning Date
- KIND 11-06-2024
- MDXG 10-30-2024
- Dividend Yield
- KIND N/A
- MDXG N/A
- EPS Growth
- KIND N/A
- MDXG N/A
- EPS
- KIND N/A
- MDXG 0.52
- Revenue
- KIND $237,605,000.00
- MDXG $342,804,000.00
- Revenue This Year
- KIND $13.92
- MDXG $9.56
- Revenue Next Year
- KIND $15.11
- MDXG $9.19
- P/E Ratio
- KIND N/A
- MDXG $18.44
- Revenue Growth
- KIND 9.99
- MDXG 10.93
- 52 Week Low
- KIND $1.32
- MDXG $5.47
- 52 Week High
- KIND $3.00
- MDXG $9.48
- Technical
- Relative Strength Index (RSI)
- KIND 43.49
- MDXG 73.10
- Support Level
- KIND $2.43
- MDXG $5.69
- Resistance Level
- KIND $2.56
- MDXG $7.67
- Average True Range (ATR)
- KIND 0.14
- MDXG 0.30
- MACD
- KIND -0.01
- MDXG 0.15
- Stochastic Oscillator
- KIND 3.10
- MDXG 89.66
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.